Status:
COMPLETED
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
Lead Sponsor:
AstraZeneca
Conditions:
Metabolic Syndrome
Dyslipidemia
Eligibility:
MALE
30-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the dose-related effect of treatment with rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-...
Eligibility Criteria
Inclusion
- Signed informed consent
- male aged 30 to 70 years of age
- LDL-C \<6 mmol/L
- HDL-C ≤1.2 mmol/L
- at least 2 of the following:
- insulin resistance (fasting glucose \>6 mmol/L or insulin \>10 mU/L or HOMA score \>2.5)
- central obesity (waist circumference \>=94 cm).
- plasma triglycerides \>=1.7 and \<4.5 mmol/L.
- blood pressure \>=130/ \>=85 mm Hg or on drug treatment for hypertension
Exclusion
- LDL cholesterol \>=6 mmol/L
- pre-existing or history of cardiovascular disease, diabetes, renal dysfunction, anaemia, history of significant dyspepsia or gastrointestinal disease
- apolipoprotein genotype E2/E2
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00240305
Start Date
April 1 2004
End Date
May 1 2006
Last Update
March 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Perth, Western Australia, Australia